<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01625026</url>
  </required_header>
  <id_info>
    <org_study_id>OCABSGS</org_study_id>
    <nct_id>NCT01625026</nct_id>
  </id_info>
  <brief_title>Obeticholic Acid in Bariatric and Gallstone Disease</brief_title>
  <acronym>OCABSGS</acronym>
  <official_title>Effects of Obeticholic Acid on Hepatic Fatty Acid/Triglyceride Metabolism and Hepatobiliary Detoxification/Elimination in Morbidly Obese and Gallstone Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sahlgrenska University Hospital, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      By binding to the nuclear receptor FXR, bile acids not only regulate their own turn-over but&#xD;
      presumably also pivotal steps in cholesterol, triglyceride and glucose metabolism as shown in&#xD;
      laboratory animals. Obeticholic acid (OCA) is a semisynthetic bile acid with very high&#xD;
      affinity to FXR. In a pharmacodynamic study the effects of OCA on bile acid, lipid and&#xD;
      glucose turn-over are studied in 20 morbidly obese and 20 gallstones patents, respectively,&#xD;
      that are administered OCA at 25 mg/day in three weeks before bariatric (BS) or gallstone (GS)&#xD;
      surgery where in addition to blood samples also biopsies are taken from the liver and in the&#xD;
      case of BS, omental and subcutaneous adipose tissue and in case of GS, gallbladder bile.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a placebo-controlled double-blind randomized trial, 20 otherwise healthy morbidly obese&#xD;
      patients scheduled for bariatric surgery, and 20 otherwise healthy gallstone patients will be&#xD;
      administered 25 mg/day INT-747 or placebo for three weeks until the day before surgery. Serum&#xD;
      from days 1 and 21 will be analyzed for routine liver tests, bile acids, a complete lipid&#xD;
      profile including FA and in addition for 7α-hydroxy-4-cholesten-3-one and FGF-19, markers for&#xD;
      bile acid synthesis and its intestinal stimulation. For the evaluation of insulin resistance&#xD;
      and possible pre-diabetes, plasma will be taken for the estimation of HOMA index and oral&#xD;
      glucose tolerance test (OGTT) will be performed at days 1 and 21. At surgery, a liver biopsy&#xD;
      (0.5-1 g) and a white adipose tissue (WAT) specimen (1 cm2) will be taken and immediately&#xD;
      frozen in liquid nitrogen for mRNA and protein preparation for quantitative RT-PCR and&#xD;
      Western analysis, respectively, histopathological NAFLD grading, and measuring of hepatic and&#xD;
      WAT lipase activity. In gallstone patients, gallbladder bile will be sampled for the&#xD;
      measurements of biliary lipids (cholesterol, phospholipids, bile acids) and the calculation&#xD;
      of the cholesterol saturation index.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of OCA on FXR-dependent metabolism</measure>
    <time_frame>Day 21</time_frame>
    <description>Primary endpoints&#xD;
relative changes in markers for insulin resistance&#xD;
relative changes in FA and TG&#xD;
relative changes in hepatic and adipose tissue lipase expression and activity&#xD;
relative changes in hepatic apical transport proteins ABCG5/8, BSEP, MDR3, MRP2&#xD;
relative changes in hepatic ER stress markers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of OCA on serum lipid levels</measure>
    <time_frame>21 days</time_frame>
    <description>Secondary endpoints&#xD;
relative changes in m RNA expression levels of genes listed under 3.ix&#xD;
relative changes in hepatic basolateral transport proteins listed under 3.x&#xD;
relative change in serum bile acids as listed under 3.xii, including INT-747&#xD;
relative changes in biliary lipids (cholesterol, phospholipids, bile acids)&#xD;
relative change in plasma 7α-hydroxy-4-cholesten-3-one and FGF-19&#xD;
relative changes in total cholesterol, LDL-C, HDL-C, Apo A1, Apo B, in Lp(A)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity</condition>
  <condition>Gallstones</condition>
  <arm_group>
    <arm_group_label>Morbid Obesity OCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obeticholic acid 25 mg/day in three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morbid Obesity Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Obeticholic acid 25 mg/day matching placebo in three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gallstones OCA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Obeticholic acid 25 mg/day in three weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gallstones Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Obeticholic acid 25 mg/day matching placebo in three weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic acid</intervention_name>
    <description>Obeticholic acid 25 mg/day in three weeks</description>
    <arm_group_label>Gallstones OCA</arm_group_label>
    <arm_group_label>Morbid Obesity OCA</arm_group_label>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo to obeticholic acid</description>
    <arm_group_label>Gallstones Placebo</arm_group_label>
    <arm_group_label>Morbid Obesity Placebo</arm_group_label>
    <other_name>Placebo INT-747</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  In the obesity group: BMI ≥35 kg/m2&#xD;
&#xD;
          -  In the gallstone group: symptomatic, ultrasound verified gallstone disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic liver disease other than NAFLD (viral hepatitis, autoimmune liver disease,&#xD;
             hemochromatosis, homozygous alpha1-antitrypsin deficiency and Wilson disease)&#xD;
&#xD;
          -  Previous gastric or small bowel surgery&#xD;
&#xD;
          -  Inflammatory bowel disease&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus (fasting blood glucose &gt;6.7 mmol/L), hypothyroidism or&#xD;
             hyperthyroidism, or other significant endocrine disease.&#xD;
&#xD;
          -  Pregnancy. A urine pregnancy test will be performed the day before start of&#xD;
             medication. Women of childbearing potential can only be included if a safe and&#xD;
             reliable contraception is used, e.g., oral contraceptives.&#xD;
&#xD;
          -  Elevations of transaminases (ALAT/ASAT) or alkaline phosphatase or bilirubin above&#xD;
             2xULN (upper limit of normal) the day before start of medication.&#xD;
&#xD;
          -  Other serious disease, including depressive disorders treated by medication&#xD;
&#xD;
          -  Patients who will not comply with the protocol.&#xD;
&#xD;
          -  A subject who is euthyroid on a stable replacement dose of thyroid hormone is&#xD;
             acceptable provided the TSH is within normal range.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanns-Ulrich Marschall, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital Gothenburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanns-Ulrich Marschall</name>
      <address>
        <city>Göteborg</city>
        <zip>411 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>June 19, 2012</study_first_submitted>
  <study_first_submitted_qc>June 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2012</study_first_posted>
  <last_update_submitted>October 15, 2016</last_update_submitted>
  <last_update_submitted_qc>October 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sahlgrenska University Hospital, Sweden</investigator_affiliation>
    <investigator_full_name>Hanns-Ulrich Marschall</investigator_full_name>
    <investigator_title>Professor of Clinical Hepatology</investigator_title>
  </responsible_party>
  <keyword>Morbidly obesity</keyword>
  <keyword>Gastric bypass</keyword>
  <keyword>Cholecystolithiasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gallstones</mesh_term>
    <mesh_term>Cholelithiasis</mesh_term>
    <mesh_term>Cholecystolithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

